ImmunityBio Stock Pre-Market (+21%): ANKTIVA Sales Explode 700%, Gains Saudi FDA Approval
ImmunityBio (IBRX) is soaring over 21% in pre-market after reporting a massive 700% YoY increase in preliminary 2025 revenue for its drug ANKTIVA and securing dual approvals in Saudi Arabia. The sentiment is euphoric, but can this biotech sustain such a massive gap up?
This is a structural, thesis-changing catalyst. The preliminary 2025 net product revenue of $113 million for ANKTIVA demonstrates explosive commercial adoption, crushing expectations.
- The revenue growth signals an accelerating sales trajectory, not a one-off event.
- Saudi FDA approval for lung cancer marks the drug’s first global nod for this indication.
- This dual catalyst of sales execution and geographic expansion fundamentally de-risks the story.
But here is the interesting part. You are reading about this 21% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Playbook On Market Open
The stock is gapping into overbought territory, setting up a classic battle between fundamental momentum and technical exhaustion. The session will depend on follow-through conviction.
- BULL CASE (Gap & Go): Strong volume holds the gap above the $4.00 psychological level. Analyst upgrades and positive commentary hit the wires, attracting institutional chasing.
- BEAR CASE (Gap & Fade): The initial morning spike fails to hold. Traders sell the news, focusing on the company’s cash burn and prior unprofitability, pushing it below the opening price.
- Heavy short interest could fuel a squeeze, but also provides a pool of future sellers.
Verdict
This is not noise; it’s a fundamental inflection. PIVOT: $4.00. If price holds above $4.00, we BUY THE OPEN and chase the momentum. If it breaks below, we FADE THE GAP, anticipating profit-taking.
Understanding price behavior can give you an edge. See more.
Want to make sure you never miss the explainer on IBRX’s next move? Stay updated with Upcoming Events and Latest Analyses
That’s for now, but so much more goes into evaluating a stock from long-term investment perspective. We make it easy with our Investment Highlights
Multi Asset Portfolios Offer More Upside With Less Risk
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices